Consumer Business An Asset To Pfizer, A Divestment Chip To Analysts
CEO Ian Read says selling the consumer business has to do more than boost Pfizer's treasury. "If there is a better mix, we are always open to it, but it has to be for strategic reasons rather than cash," he says.
You may also be interested in...
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.
Pfizer didn't cite its consumer health business in announcing it will retain current structure, but best-selling Lipitor's cholesterol treatment indication is the most coveted indication yet to be available OTC.
The $160bn mega-merger that never came to be was exciting to watch unfold from beginning to the stunning end, when it was derailed by the US government. “The Pink Sheet” followed every twist and turn along the way.